20221027104337.jpg)
William K. Oh, MD, has been appointed as Medical Director of Smilow Cancer Hospital at Greenwich Hospital, as well as Director of Precision Medicine for Yale Cancer Center and Smilow Cancer Hospital.
20221027104337.jpg&width=400&height=400)
A new study led by Yale Cancer Center researchers at Yale School of Medicine titled, "Living Flat: Stories from Women of Color After Mastectomy," explains how cultural factors, spirituality, and personal beliefs play an important role in the lives of women of color after mastectomies.
Dr. David Braun, a medical oncologist at Yale Cancer Center, will be awarded the Christopher G. Wood Rising Star Award by the Kidney Cancer Association at November's International Kidney Cancer Symposium.
Significantly more younger people underwent colorectal cancer screening after the recommended age to begin such screening was lowered, Yale researchers report. In a new study of 10 million insured people aged 45 to 49, researchers found that a recommendation by the United States Preventative Services Task Force to drop the age for starting colorectal cancer screening by five years to age 45 was highly effective — tripling the rate of screening overall — but the magnitude of increase was significantly smaller for low-income and rural populations.
A new pathology tool created at Yale harnesses barcode technology and shows potential for use in cancer diagnoses. The technology, Patho-DBiT (pathology-compatible deterministic barcoding in tissue), was discussed in a new study that published Sept. 30 in the journal Cell. Co-corresponding author Dr. Mina Xu, a Yale Cancer Center (YCC) member, professor of pathology at Yale School of Medicine (YSM), and the YSM director of hematopathology, shared her enthusiasm for the new tool.
Comprehensive gene panel testing, one of the exciting new tools in cancer diagnostics, warrants greater scrutiny — as does a federal program aimed at speeding up the review process for proposed new medical technologies. Those are conclusions of Yale medical experts who studied both and published a report in the Journal of the National Cancer Institute on Sept.
The newer, 3D form of breast screening, known as digital breast tomosynthesis (DBT), is more effective at detecting breast cancer than traditional 2D digital mammography (DM). That’s the conclusion of an analysis of 13 years’ worth of screening data conducted by Yale Cancer Center researchers.
Ancient Chinese traditional medicine significantly reduces the side effects of rectal cancer treatments that, in some patients, can be so toxic that treatment must be paused, or stopped, which diminishes its effectiveness.
The latest trial of a new antibody drug that delivers potent chemotherapy directly to cancer cells for patients with advanced or recurrent endometrial cancer moves ahead to be studied further in a phase III trial.
In addition to earning the sixth spot nationally in Psychiatry, Yale New Haven Hospital ranked well in Obstetrics and Gynecology (#19), Otolaryngology (Ear Nose and Throat) (#27), Geriatrics (#28), Diabetes and Endocrinology (#29) Pulmonology and Lung Surgery (#31), Urology (#31), Heart and Heart Surgery (#43) Cancer (#45), Neurology and Neurosurgery (#48) and Gastroenterology and GI Surgery (#50).
Sneaking by cancer’s defenses, by disguising tumor-fighting antibodies inside the molecules cancer uses to nourish tumor growth, is the basis of a novel therapy from Yale Cancer Center researchers at the Yale School of Medicine (YSM).
Patients with pancreatic cancer who received chemotherapy both before and after surgery experienced longer survival rates than would be expected from surgery followed by chemotherapy, according to a new study from researchers at Yale Cancer Center (YCC) and Yale School of Medicine. The study, published June 20 in JAMA Oncology, included patients with pancreatic ductal adenocarcinoma (PDAC), which accounts for 90% of pancreatic cancers.
New research from Yale Cancer Center reveals first-of-its-kind data from a phase I study in patients with hormone receptor positive HER2-negative metastatic breast cancer. The results, which assess the safety and efficacy of a treatment known as PF-07248144, offer new hope for treating this aggressive type of breast cancer.
Testosterone fuels the growth of prostate cancer. The target of testosterone is the androgen receptor. Metastatic prostate cancer is treated by reducing levels of testosterone, and despite initial responses to treatment, nearly all patients become resistant to androgen deprivation therapy.
Patients being treated for HPV-related oropharynx cancer might need less radiation therapy typically given post-surgery, according to a new study.
“The COAST study, which we began five years ago, involves patients who get chemotherapy and radiation therapy for lung cancer. And now we know that we can improve the outcome with a drug called durvalumab,” explained Dr. Herbst, who will present the findings at ASCO.
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right